Memory Disorders Research
Alzheimer’s Disease
TRAILBLAZER-ALZ2
Investigator: Paul Schulz, MD
Purpose: Eli Lilly and Company/Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease.
Key Inclusion Criteria: 60-85 yrs with mild AD symptoms; ability to undergo PET scans; requires study partner.
Enrollment Status: Opening in near future
Contact Us: To learn more about this trial, please fill out this short online form »
The Oral Microbiome in Patients with Dementia
Investigator: Paul Schulz, MD, Cameron Jeter, MD
Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner.
Enrollment Status: Opening in near future
Contact Us: To learn more about this trial, please fill out this short online form »
Stem Cell Therapy for Early AD
Investigator: Paul Schulz, MD
Purpose: Stem Cell Therapy for Early AD
Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner
Enrollment Status: Opening in the near future
Contact Us: To learn more about this trial, please fill out this short online form »
Plasma Exchange for the Treatment of Early AD
Investigator: Paul Schulz, MD
Purpose: Plasma Exchange for the treatment of Early AD
Key Inclusion Criteria: 50 -90 yrs mild cognitive impairment or early AD symptoms; requires study partner
Enrollment Status: Opening in near future
Contact Us: To learn more about this trial, please fill out this short online form »
Clinical Trials
Please fill out the fields to receive information about an ongoing UTHealth Neurosciences clinical trial.